Withings has already made a name for itself as a maker of smart scales and ultra-stylish activity trackers. Now, the French health-tech company is making a foray into the world of medical analysis, building a device to scan people’s urine. It’s initially intended as a way of supporting decentralized clinical trials, the company hopes to offer it as a consumer health-tech device in the future. Say hello to U-Scan.

U-Scan is a pebble-shaped device that hangs from a plastic tab on the side of your toilet bowl, much like a deodorizer block. The hardware, 90mm in diameter, is intended to sit on the porcelain where most people’s pee streams would land. There’s a collection inlet at the lowest point, and a sensor will detect the presence of urine and trigger a pump you pull a small quantity into its body. From there, the sample is pumped into a microfluidic system which triggers a chemical reaction.

Sitting underneath the U-Scan itself will be a cartridge, which contains the specific test that you’re looking for. The company has, so far, partnered with two medical centers in Europe to explore ways of discovering renal lithiasis and bladder cancer. It’s hoped that the system will eventually be used to mass-screen for cancer markers and support medical studies.

In terms of the consumer units, the company has developed U-Scan Cycle Sync, designed to be used for period tracking. The idea is to provide detailed, regular testing to enable fine-grain cycle tracking without the need for calendar apps. As well as predicting your menstrual cycle, the system says it’ll predict your ovulation window, hydration levels and nutrient levels.

The other is U-Scan Nutri Balance, which offers a “detailed metabolic guide to hydration and nutrition.” This will look at your water balance, nutrient levels, fat metabolism and quantities of vitamin C found in your pee. Most crucially, you'll be able to monitor your ketone levels, as well as the pH of your urine, good for determining if you’re eating a healthy enough diet.

When processed, the results of the tests are shared to a server over WiFi or Bluetooth, and then the cartridge will reset with a fresh test pod. The company says that U-Scan is sufficiently smart to distinguish different users, such as various family members in a home, and separate tests accordingly.

Withings has also said that its system conforms to the highest security standards, and that its data will always be held in France, in a GDPR-compliant setup. It says that U-Scan will run for three months before needing a recharge (over USB-C) and a replacement cartridge.

In terms of pricing, and availability, you’ll expect that whatever date Withings says, it may be delayed due to regulatory approvals. The company says that U-Scan will be first made available in Europe at some point in Q2, 2023, with the Nutri Balance and Cycle Sync cartridges. A starter kit, with one reader and cartridge, will be priced at €499.95 ($530), while replacement cartridges are expected to cost €30 ($31). A US release will take place at some point afterward, whenever the FDA decides to clear the product for consumer use.

We often see a bunch of healthcare-oriented gadgets coming out of CES, but Vivoo's latest offering isn't exactly a fitness tracker. The company has unveiled a smart toilet device that can test your urine and send the results to your phone.

The tech is built into a device that can clip onto existing toilets. Vivoo, which has offered at-home urine tests for the last few years, designed the system with residential care, the elderly and healthcare service providers in mind. It could give those who simply want to know more about what's going on with their body some additional data. 

The device will automatically align a testing strip with a person's urine stream, according to Vivoo, which says this approach should reduce the risk of mess involved with a handheld strip. An optical reader akin to those used in hospitals analyzes the urine sample for four wellness parameters and delivers the results to the Vivoo app within 90 seconds. The company suggests that the results can offer "indications of certain deficiencies or abnormalities" and help with early detection of some conditions.

Vivoo says its app can provide data on your body's water, magnesium, pH, protein and sodium levels, among others, though disclaimers on its website say these measurements are not intended for medical use. It offers nutrition advice based on the results and Vivoo may suggest personalized supplements.

The company claims it's easy to clean the smart toilet device. It adds that the system has an ergonomic design. However, based on images Vivoo provided, the device is positioned at the front of the toilet seat and it looks fairly cumbersome. Folks who need to sit to pee may find it difficult to position their legs around it, such as the elderly and those with mobility issues.

When doctors need to confirm an Alzheimer's diagnosis, they often turn to a combination of brain imaging and cell analysis. Both have their downsides. The latter involves a lumbar puncture, an invasive and painful procedure that’s more commonly known as a spinal tap. A doctor will insert a needle into the lower back to extract a sample of the patient’s cerebrospinal fluid. A lab technician then tests the sample for signs of progressive nerve cell loss and excessive amyloid and tau protein accumulation. MRI scans are less invasive but they’re often expensive and accessibility is an issue; not every community has access to the technology.

The next best tool for diagnosing Alzheimer’s disease is a blood test. While some can detect abnormal tau protein counts, they’re less effective at spotting the telltale signs of neurodegeneration. But that could soon change. This week, in the journal Brain, a multinational team made up of researchers from Sweden, Italy, the UK and US detailed a new antibody-based blood test they recently developed. The new test can detect brain-derived tau proteins, which are specific to Alzheimer’s disease. Following a study of 600 patients, the team found their test could reliably distinguish the illness from other neurodegenerative diseases.

Dr. Thomas Karikari, a professor of psychiatry at the University of Pittsburgh and one of the co-authors of the study, told The Guardian he hopes the breakthrough could help other researchers design better clinical trials for Alzheimer’s treatments. “A blood test is cheaper, safer and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s and selecting participants for clinical trial and disease monitoring,” he said. There’s more work to be done before the test makes its way to your local hospital. To start, the team needs to validate that it works for a wide variety of patients, including those who come from different ethnic backgrounds.

Health company Movano has teased its first smart ring, the Evie, designed for health, fitness and cycle tracking. It looks like a rival to Oura's latest smart ring and other health-tracking wearables, though the company says it's "designed uniquely for women." Movano plans to provide a closer look next week at CES 2023.

The ring made its debut at CES 2022 with no name and a similar design, but Movano has since changed course on price and other factors. It will sell the ring sometime in 2023 at a one-time price below $300 (there's no exact date or price yet), rather than using a subscription model as it said last year. 

It offers many of the health metrics seen on Oura's ring and wearables from Apple and others. It can measure heart rate, blood-oxygen, skin temperature variability, steps, calories, sleep, period and ovulation tracking, and more. Wearers will can get advice from health experts inside the app and it will meet medical device manufacturing standards, the company promised.

"As a medical device, Evie will go beyond the status quo of other wearables on the market," said Movano CEO John Mastrototaro. "We are bringing together medical grade biometric data and insights in a comfortable and contemporary wearable."

With the ability to measure steps, calories burned and specific activities, Evie can also be used as a fitness tracker. However, it's primary purpose is to give a picture of overall health, "turning biometric data into actionable insights," Movano wrote in the press release.

The company also promises security and privacy when transferring data to the cloud or health providers. It's currently seeking all-important FDA clearance, which will dictate the release date. If that takes too long, though, it may come to market as a wellness device at first. The Evie smart ring will only be released in the US to start with, but may come to other markets later — we should learn more about it next week at CES 2023. 

It’s been six years since Tesla, SpaceX (and now Twitter) CEO Elon Musk co-founded brain-control interfaces (BCI) startup, Neuralink. It’s been three years since the company first demonstrated its “sewing machine-like” implantation robot, two years since the company stuck its technology into the heads of pigs — and just over 19 months since they did the same to primates, an effort that allegedly killed 15 out of 23 test subjects. After a month-long delay in October, Neuralink held its third “show and tell” event on Wednesday where CEO Elon Musk announced, "we think probably in about six months, we should be able to have a Neuralink installed in a human."

Neuralink has seen tumultuous times in the previous April 2021 status update: The company’s co-founder, Max Hodak, quietly quit just after that event, though he said was still a “huge cheerleader” for Neuralink’s success. That show of confidence was subsequently shattered this past August after Musk reportedly approached Neuralink’s main rival, Synchron, as an investment opportunity. 

Earlier in February, Neuralink confirmed that monkeys had died during prototype testing of its BCI implants at the ​​University of California, Davis Primate Center but rejected accusations by the Physicians Committee for Responsible Medicine of animal cruelty. In July, Synchron beat Neuralink to market when doctors at Mount Sinai Hospital in New York successfully installed the company's inch-and-a-half long device into a person living with ALS. The patient, who has lost their ability to move and communicated independently, should be able to surf the web and send text messages using the device to translate their thoughts into computer commands. That same month, an affair Musk had with a Neuralink executive, who is now pregnant with his twins, also came to light. 

Neuralink is still working towards gaining FDA approval for its implant, though the company was awarded the agency's Breakthrough Device Designation in July 2020. This program allows patients and caregivers more "timely access" to promising treatments and medical devices by fast tracking their development and regulatory testing. As of September, 2022 the FDA has granted that designation to 728 medical devices. 

The FDA has also updated its best practices guidance regarding clinical and nonclinical BCI testing in 2021. "The field of implanted BCI devices is progressing rapidly from fundamental neuroscience discoveries to translational applications and market access," the agency asserted in its May guidance. "Implanted BCI devices have the potential to bring benefit to people with severe disabilities by increasing their ability to interact with their environment, and consequently, providing new independence in daily life."

“In many ways it’s like a Fitbit in your skull, with tiny wires,” Musk said of Neuralink's device during the 2021 livestream event. The device relies on as many as 1,024, 5-micron diameter leads "sewn" into a patient's grey matter to form connections with the surrounding neurons, providing high-resolution sampling of the brain's electrical emissions and translating between analog electrical impulses and digital computer code. Theoretically, at least. So far, all Neuralink has accomplished is getting a monkey to play Pong without a joystick.

“We hope to have this in our first humans, which will be people that have severe spinal cord injuries like tetraplegics, quadriplegics, next year, pending FDA [Food and Drug Administration] approval,” Musk told the Wall Street Journal’s CEO Council summit in January. 

Developing...

Amazon has launched a new virtual health service that gives you a way to consult healthcare professionals for common conditions and get prescriptions for them without heaving to make a video call. This new product is called Amazon Clinic, and it offers a text-based solution that connects you with third-party virtual care options. You can choose among Amazon's partner telehealth providers, but the purpose of your consultation has to be in the service's list of accepted conditions, which include acne, hair loss, acid reflux, pink eye, sinusitis and UTI. You can also use the service to get prescription renewals for conditions like asthma, high blood pressure and migraine. 

This is but the latest product Amazon has introduced in its bid to delve deeper into the healthcare sector. The e-commerce giant launched Amazon Pharmacy to deliver discounted prescription medicine to Prime members in 2020, and it entered a deal to purchase primary healthcare company One Medical for $3.9 billion in July. Amazon used to offer an app-based telehealth service called Amazon Care to its employees and other companies across the US, but it was shut down by the end of September. According to a previous Washington Post report, company senior vice president of health Neil Lindsay told employees that while "enrolled members have loved many aspects of Amazon Care, it is not a complete enough offering for the large enterprise customers [the company has] been targeting, and wasn’t going to work long-term."

Unlike Care, Clinic wasn't designed to be an enterprise offering. At the beginning of your consultation on the service, you'll have to select your condition and choose your preferred provider from the list of partners before answering a short questionnaire. You'll then be connected to a secure messaging portal where you can chat with a healthcare professional, who'll send you a personalized treatment plan. They can also send your preferred pharmacy — one of the options, of course, is Amazon Pharmacy — any necessary prescriptions. You'll remain connected to your healthcare professional for up to two weeks after your initial chat, and you can send them follow-up messages within that time. 

While the service doesn't accept insurance right now, you can pay with an FSA or HSA debit card or get your receipt reimbursed when possible. You do have to pay a flat fee upfront, which is dependent upon your condition. Amazon says that the cost of care is equivalent or less than the average copay in many cases. As for medication, coverage varies, but you can use insurance to pay for it. Amazon Clinic is only available in 32 states at the moment, though the company is hoping to expand its reach to additional states over the coming months. 

Back at I/O in May, Google announced Health Connect, a platform it worked on with Samsung to enable health and fitness apps to share data more easily with each other while maintaining privacy measures. That initiative is taking another step forward today, as the Health Connect app has moved out of early access and into beta on the Play Store, while several health and fitness apps are rolling out integrations.

Peloton, Oura, WeightWatchers, MyFitnessPal, Flo, Lifesum, Tonal, Outdooractive and Proov Insight have joined Google and Samsung's own services: Fitbit, Google Fit and Samsung Health. The integrations mean that when you take on a workout in one app, you can share your stats across the Health Connect ecosystem. The likes of Oura and WeightWatchers will be able to take into account your Peloton workouts, for instance.

Google and Samsung have made it easier for health and fitness app developers to tap into such information by creating a standardized data schema. This supports more than 40 data types across six categories: activity, body measurement, cycle tracking, nutrition, sleep and vitals. Google notes that it only takes a few lines of code for apps to read and write any of these data types through Health Connect.

One of the key benefits for users is that they'll be able to manage permissions for all these integrations in one place. Health Connect includes granular controls over which types of data each third-party app can access. You can also block all apps from accessing Health Connect data with a couple of taps.

Bioprinted body parts could prove vital to future medical treatments, and scientists are going to great lengths to test it — in a very literal sense. NASA, Redwire and the Uniformed Services University of the Health Sciences Center for Biotechnology (4DBio3) are sending a new 3D printer to the International Space Station, Redwire's BioFabrication Facility, to bioprint a human knee meniscus in orbit and study the result on Earth. Ideally, this will lead to treatments for the meniscal injuries that US soldiers all-too-frequently face.

Redwire hopes to 3D print whole organs in space, although it characterizes this as a "long-term" goal. The company is also using NASA's Advanced Plant Habitat for a project to identify genes for space-friendly plants. Another investigation will use a NASA furnace to create and demo passive cooling for electronics in low gravity.

The BFF printer will fly to the ISS aboard a supply rocket launching as soon as November 6th from NASA's Wallops Island spaceport. The mission will carry three extra payloads.

This isn't NASA's first spaceborne 3D printer. Last year, NASA carried a Redwire printer to the ISS to demonstrate printing lunar soil. That technology could one day help Moon colonists build habitats without carrying an abundance of supplies from Earth. The bioprinter is more immediately practical, of course. If the research pans out, doctors could replace damaged body parts without resorting to donations or inorganic implants.

YouTube is attempting to make it easier for folks to find reliable and high-quality health information on the platform. It's opening up its health product features to certain healthcare professionals and information providers in the US. It started offering those features last year to educational institutions, public health departments, hospitals and government bodies. "This new step will allow us to expand to include high quality information from a wider group of healthcare channels," Dr. Garth Graham, the global head of YouTube Health, wrote in a blog post.

The features include labels under videos that clearly state the information is coming from a healthcare professional or accredited organization. When a user searches for a term such as "bipolar" or "breast cancer," they may see a carousel of videos under the label “From health sources” near the top of the search results.

YouTube says healthcare professionals can apply for the program starting today. They'll need to submit proof of their medical license and for their YouTube account to be in good standing. They'll also need to follow the Council of Medical Specialty Societies, the National Academy of Medicine and the World Health Organization best practices for sharing health information. YouTube plans to expand the program to more markets and other types of medical specialties.

Helping people obtain credible health information from a verified professional is inherently a positive move. YouTube will still have to tread carefully with this program, given the COVID-19 and vaccine misinformation that has been rife on the platform over the last few years. Meanwhile, YouTube points out that people shouldn't consider health-related information they learn from verified professionals as medical advice (and nor will the videos apply to everyone). You'd still be best served to get in touch with a healthcare provider if you have a medical concern and to contact emergency services if the need arises.

Microsoft has been gradually updating its Seeing AI app since its launch in 2017, expanding language support and general functionality over the years. Today, the company is announcing a new feature that would let Seeing AI read out detailed information when users scan the barcodes of products by healthcare company Haleon. The feature is rolling out today for US and UK users on the free app, which is only available on iOS. The company says an Android version will be available "in the future."

In a press release, Microsoft and Haleon said "With today’s launch in honor of World Sight Day, people can now hear packaging information through the Microsoft Seeing AI app by scanning the barcode of Haleon products." Users who are blind, have trouble reading or have low literacy can use the app to scan more than 1,500 Haleon products like Advil, Excedrin, Theraflu, Emergen-C and more, and their device will read out product information, instructions, ingredients "and other crucial details."

The press release also noted that "The Seeing AI collaboration with Microsoft is one of Haleon’s first new initiatives to champion health inclusivity." We may be seeing more from the healthcare company in future, but for now, it's nice to see that people with visual impairments or low literacy can more easily and independently learn about the drugs they are considering or consuming. That is, at least, if they use iOS.